Published Online
on August 10, 2006

A more recent version of this article appeared on September 1, 2006

This Article Full Text (PDF) All Versions of this Article: 37/9/2368    most recent 01.STR.0000236496.30106.4bv1 Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wilczak, N. Articles by De Keyser, J. Search for Related Content PubMed PubMed Citation Articles by Wilczak, N. Articles by De Keyser, J. Pubmed/NCBI databases Substance via MeSH Medline Plus Health Information Stroke Related Collections Fibrinolysis Acute Cerebral Infarction Emergency treatment of Stroke Thrombolysis

Submitted on April 4, 2006
Revised on May 20, 2006
Accepted on June 19, 2006

Intravenous Tissue Plasminogen Activator in Patients With Stroke Increases the Bioavailability of Insulin-Like Growth Factor-1

Nadine Wilczak PhD; Jan Willem Elting MD; Daniel Chesik PhD; Ido P. Kema MD; and Jacques De Keyser MD^*

From the Departments of Neurology (N.W., J.W.E., D.S., J.D.) and Laboratory Medicine (I.P.K.), University Medical Center Groningen, Groningen, The Netherlands.

^* To whom correspondence should be addressed. E-mail: j.h.a.de.keyser{at}neuro.umcg.nl.

Background and Purpose--Insulin-like growth factor (IGF)-1 has potent neuroprotective properties. We investigated the effects of intravenous administration of tissue plasminogen activator (tPA) on serum levels of IGF-1 and IGF-binding protein (IGFBP)-3 in patients with acute ischemic stroke.

Methods--Serum levels of total IGF-1, free IGF-1, and IGFBP-3 were measured by radioimmunoassay in 10 patients with ischemic stroke treated with intravenous tPA (0.9 mg/kg body weight) and 10 untreated controls.

Results--During tPA treatment, total IGF-1 and IGFBP-3 serum levels did not change, but there was an 70% increase in free IGF-1 serum levels from 0.98±0.25 at baseline to 1.69±0.18 nmol/L at the end of the 1-hour infusion (P=0.01).

Conclusions--Intravenous therapy with tPA enhances the bioavailability of IGF-1.

Key words: acute stroke • insulin-like growth factor 1 • neuroprotection • thrombolysis • tissue plasminogen activator

This article has been cited by other articles:

				R. Kooijman, S. Sarre, Y. Michotte, and J. De Keyser Insulin-Like Growth Factor I: A Potential Neuroprotective Compound for the Treatment of Acute Ischemic Stroke? Stroke, April 1, 2009; 40(4): e83 - e88. [Abstract] [Full Text] [PDF]